Adma Biologics Inc (ADMA) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Adma Biologics Inc   (NASDAQ: ADMA)


Adma Biologics Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Adma Biologics Inc's ROI in the third quarter of 2026?
Adma Biologics Inc achieved a return on average invested assets (ROI) of 29.2 % in its third quarter of 2026, this is above ADMA's average return on investment of -48.57%.
Adma Biologics Inc invested over the 12 months ending in its third quarter of 2026 $625 million

ROI has improved compared to 28.94% in the second quarter of 2026, due to net income growth.

Within the Healthcare sector 39 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 169, from total ROI ranking in the second quarter of 2026 at 207.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 32.93 % 37.25 % 41.56 % 49.61 % 55.23 %
Y / Y Net Income Change TTM -12.91 % -19.13 % -5.35 % -0.59 % 483.27 %
Investment (TTM) in Millions 677 643 592 588 513
Return On Investment (TTM) 29.2 % 28.94 % 30.38 % 28.75 % 44.57 %
ADMA's Overall Ranking # 169 # 207 # 92 # #
Seq. Investment Change TTM 7 % 7.25 % 6.52 % 8.74 % 10.48 %
Seq. Net Income Change TTM 7.96 % 2.18 % 12.54 % -29.85 % 0.25 %
Net Income (TTM) in Millions 182 169 165 147 209

ADMA Company Profile >> Back to ADMA Roi Comparisons >> See Annual ADMA Return On Investment



Return On Investment ADMA's Ranking
Within: No.
Industry # 7
Sector # 40
Overall # 169

Return On Investment Statistics
High Average Low
57.87 %
-48.57 %
-186.97 %
(Dec 31 2024)   (Sep 30 2013)



  News about Adma Biologics Inc Return on Investment ROI

Navigating Double Currents ADMA Biologics Financial Gains and Legal Scrutiny,

October 15, 2024

Investigation of ADMA Biologics Underway Amidst Company’s Financial Milestones In recent developments, ADMA Biologics Inc. a biopharmaceutical company headquartered in New Jersey and listed on NASDAQ under the ticker ADMA, has come under scrutiny from the law firm Bronstein, Gewirtz and Grossman, LLC. The firm announced on October 15, 2024, that it is investigating potential claims on behalf of investors who have purchased securities from ADMA Biologics. This legal investigation aims to explore whether there have been any mishandlings or breaches of fiduciary duty that shareholders ought to be aware of.Investors who have placed their stakes in ADMA Biologics are being encouraged to reach out to the firm to provide pertinent information and possibly participate in the investigation. Additional details can be found on their official website, underlining the importance of transparency and investor protection in financial undertakings.

ADMA Biologics Makes Headway in Debt Reduction and Financial Performance Amidst Recent Challenges,

August 14, 2024

ADMA Biologics Announces Partial Paydown of Revolving Credit Facility
In a recent press release, ADMA Biologics Inc announced that it has utilized its cash on hand to partially pay down its revolving credit facility with Ares Capital, amounting to $30 million. The company emphasized that this repayment was made with no prepayment penalties involved.
ADMA Biologics, a biopharmaceutical company that develops and manufactures plasma-based biologics, has been making significant strides in its financial position. The announcement of the partial paydown comes at a time when the company s stock has reached its 52-week high, reflecting positive market sentiment.





Financial Statements
Adma Biologics Inc's III. Quarter Investments $ 677 Millions ADMA's Balance sheet
Adma Biologics Inc's III. Quarter Income $ 50 Millions Quarterly ADMA's Income Statement
ADMA's Income by Division See ADMA's Income by Division


ADMA Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 560 423 268 297 238
Y / Y Investment Growth 32.3 % 57.99 % -9.79 % 24.57 % 30 %
Net Income in Millions 147 198 -28 -66 -72
Y / Y Net Income Growth -25.67 % - - - -
Annual Return On Investment 26.24 % 46.7 % -10.54 % -22.19 % -30.05 %


Annual Roi Comment
In the fiscal year 2025 ROI decreased relative to the previous year to 26.24 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ADMA's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ADMA's Competitors
Subscribers only: Roi for Adma Biologics Inc's Suppliers
Subscribers only: Return On Investment for ADMA's Customers

Other Ratios
ADMA's Roa ADMA's Inventory Turnover Ratio ADMA's Growth Rates ADMA's Dividend Statistics
ADMA's Profitability Ratios ADMA's Asset Turnover Ratio ADMA's Dividend Growth
ADMA's Roe ADMA's Valuation Ratios ADMA's Financial Strength Ratios ADMA's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Exelixis Inc   75.01 %
Ironwood Pharmaceuticals inc   68.68 %
Rigel Pharmaceuticals Inc  68.50 %
Alnylam Pharmaceuticals Inc   63.14 %
Idexx Laboratories Inc  52.51 %
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Standard Biotools Inc   23.91 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Intuitive Surgical Inc   16.30 %

Date modified: 2026-11-06T12:57:32+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.